The Economic Burden of Management of Pituitary Adenomas: A Propensity-Score-Matched Cost Analysis

Overview

Journal J Otolaryngol Head Neck Surg

Publisher Sage Publications

Date 2025 Jan 27

PMID 39868520

Authors

Lisa Caulley

Andrea Lasso

Brandon Zagorski

Andrew S Wilton

Refik Saskin

Nick Sahlollbey

Jeanne M Seguin

Kednapa Thavorn

Mary-Anne Doyle

Janine Malcolm

Fahad AlKherayf

Stephanie Johnson-Obaseki

David Schramm

Shaun Kilty

Affiliations

Soon will be listed here.

Abstract

Importance: Pituitary adenomas (PAs) present a notable economic burden on healthcare systems due to their management's reliance on multimodal, often costly interventions.

Objective: To determine total and relative healthcare costs for PAs at Ontario-based institutions.

Design: A retrospective, propensity-score-matched cohort analysis.

Setting: Ontario, Canada, encompassing public healthcare facilities and covering costs over a 6-year study period.

Participants: Adults diagnosed with PA (n = 1675) between April 1, 2013, and March 31, 2019, compared to a general population cohort and a hospitalized control cohort matched on demographics and health factors.

Intervention/exposures: Analysis of healthcare cost components (inpatient, outpatient, and diagnostic services) and cost trajectories postsurgery for PAs.

Main Outcome Measures: Primary outcome was total annualized healthcare costs for patients with PA relative to the general and hospitalized cohorts. Relative costs were estimated using a negative binomial regression model.

Results: Of 1675 patients with PA, total annualized costs were $49,992. Highest total costs were associated with inpatient hospitalization ($24,796) and physician services/diagnostic evaluations ($20,075). After propensity score matching, patients with PA had 12.7 times higher costs [95% confidence interval (CI) (10.9, 14.8), < .0001] during the preadmission/admission period, which remained elevated postoperatively ( < .05). Total costs did not differ between patients with PA and the hospitalized cohort [RR 0.97, 95% CI (0.92, 1.03); = .3271] in the preadmission/admission period; however, follow-up costs were 37% lower for patients with PA in the 1st follow-up year [RR 0.63, 95% CI (0.51, 0.77); < .0001], and up to 50% lower by the 5th year [RR 0.50, 95% CI (0.36, 0.68); < .0001].

Conclusions: This study provided a comprehensive assessment of the economic burden of PAs on the publicly-funded healthcare system. Patients with PA had higher annualized total costs across all observed time periods compared to the general population and lower annualized total costs compared to patients admitted to a surgical ward.

Relevance: This study highlights the financial impact of PA management on healthcare resources and provides a basis for future research aimed at cost-efficiency improvements in long-term PA care.

References

Ament J, Yang Z, Khatchadourian V, Strong E, Shahlaie K . Cost-Effectiveness of Endoscopic Versus Microscopic Transsphenoidal Surgery for Pituitary Adenoma. World Neurosurg. 2017; 110:e496-e503. DOI: 10.1016/j.wneu.2017.11.046. View

Reese J, Twitchell S, Wilde H, Azab M, Guan J, Karsy M . Analysis of Treatment Cost Variation Among Multiple Neurosurgical Procedures Using the Value-Driven Outcomes Database. World Neurosurg. 2019; 126:e914-e920. DOI: 10.1016/j.wneu.2019.03.010. View

Asemota A, Ishii M, Brem H, Gallia G . Comparison of Complications, Trends, and Costs in Endoscopic vs Microscopic Pituitary Surgery: Analysis From a US Health Claims Database. Neurosurgery. 2017; 81(3):458-472. DOI: 10.1093/neuros/nyx350. View

Guan J, Karsy M, Bisson E, Couldwell W . Patient-Level Factors Influencing Hospital Costs and Short-Term Patient-Reported Outcomes After Transsphenoidal Resection of Sellar Tumors. Neurosurgery. 2017; 83(4):726-731. DOI: 10.1093/neuros/nyx471. View

Little A, Chapple K, Jahnke H, White W . Comparative inpatient resource utilization for patients undergoing endoscopic or microscopic transsphenoidal surgery for pituitary lesions. J Neurosurg. 2014; 121(1):84-90. DOI: 10.3171/2014.2.JNS132095. View

McLaughlin N, Martin N, Upadhyaya P, Bari A, Buxey F, Wang M . Assessing the cost of contemporary pituitary care. Neurosurg Focus. 2015; 37(5):E7. DOI: 10.3171/2014.8.FOCUS14445. View

Molitch M . Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017; 317(5):516-524. DOI: 10.1001/jama.2016.19699. View

Tarricone R . Cost-of-illness analysis. What room in health economics?. Health Policy. 2005; 77(1):51-63. DOI: 10.1016/j.healthpol.2005.07.016. View

Lobatto D, Vliet Vlieland T, van den Hout W, de Vries F, de Vries A, Schutte P . Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery. Endocrine. 2020; 69(1):175-187. PMC: 7343751. DOI: 10.1007/s12020-020-02308-2. View

10.

Villwock J, Villwock M, Deshaies E, Goyal P . Significant increases of pituitary tumors and resections from 1993 to 2011. Int Forum Allergy Rhinol. 2014; 4(9):767-70. DOI: 10.1002/alr.21356. View

11.

Saad M, Salze B, Trillat B, Corniou O, Vallee A, Le Guen M . Association between Preoperative Medication Lists and Postoperative Hospital Length of Stay after Endoscopic Transsphenoidal Pituitary Surgery. J Clin Med. 2022; 11(19). PMC: 9572419. DOI: 10.3390/jcm11195829. View

12.

Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs A, Carswell C . Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022; 376:e067975. PMC: 8749494. DOI: 10.1136/bmj-2021-067975. View

13.

Khalafallah A, Shah P, Huq S, Jimenez A, Patel P, London Jr N . The 5-factor modified frailty index predicts health burden following surgery for pituitary adenomas. Pituitary. 2020; 23(6):630-640. DOI: 10.1007/s11102-020-01069-5. View

14.

Neville I, Urena F, Quadros D, Solla D, Lima M, Simoes C . Safety and costs analysis of early hospital discharge after brain tumour surgery: a pilot study. BMC Surg. 2020; 20(1):105. PMC: 7227314. DOI: 10.1186/s12893-020-00767-y. View

15.

Dekkers A, de Vries F, Zamanipoor Najafabadi A, van der Hoeven E, Verstegen M, Pereira A . Costs and Its Determinants in Pituitary Tumour Surgery. Front Endocrinol (Lausanne). 2022; 13:905019. PMC: 9302462. DOI: 10.3389/fendo.2022.905019. View

16.

Broder M, Neary M, Chang E, Cherepanov D, Katznelson L . Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary. 2013; 17(4):333-41. DOI: 10.1007/s11102-013-0506-0. View

17.

Thomas J, Gadgil N, Samson S, Takashima M, Yoshor D . Prospective trial of a short hospital stay protocol after endoscopic endonasal pituitary adenoma surgery. World Neurosurg. 2013; 81(3-4):576-83. DOI: 10.1016/j.wneu.2013.11.014. View

18.

Swearingen B, Wu N, Chen S, Pulgar S, Biller B . Health care resource use and costs among patients with cushing disease. Endocr Pract. 2011; 17(5):681-90. DOI: 10.4158/EP10368.OR. View

19.

Parasher A, Lerner D, Glicksman J, Miranda S, Dimentberg R, Ebesutani D . Drivers of In-Hospital Costs Following Endoscopic Transphenoidal Pituitary Surgery. Laryngoscope. 2020; 131(4):760-764. DOI: 10.1002/lary.29041. View

20.

Karsy M, Brock A, Guan J, Bisson E, Couldwell W . Assessment of Cost Drivers in Transsphenoidal Approaches for Resection of Pituitary Tumors Using the Value-Driven Outcome Database. World Neurosurg. 2017; 105:818-823. DOI: 10.1016/j.wneu.2017.05.148. View